Neutrophil Activation Markers and Rheumatoid Arthritis Treatment Response to the JAK1/2 Inhibitor Baricitinib
Authors' conclusion
Neutrophil activation markers may add clinical value in predicting treatment response to baricitinib and other drugs targeting RA.
Study context
- Population
- Patients with rheumatoid arthritis (RA) in randomised baricitinib trials and healthy controlswhole-blood RNA n = 1,651
- Participants
- 271 vs 39
- Comparison
- Baricitinib 2 and 4 mg vs placebo; RA vs healthy controls
- RAn = 271
- Healthy controlsn = 39reference
- Outcome
- Neutrophil activation markers
Methodological detailsbiomarker analysis of randomised trials, placebo-controlled
- Biomarker analysis of randomised trials
- Placebo-controlled
Main finding
As reported in the abstract
- Baricitinib reduced soluble calprotectin at 12 and 24 weeks, especially in ACR20 responders
- Whole-blood RNA: similar changes in calprotectin and Fcα receptor I with baricitinib in three RCTs
- Baseline neutrophil activation score (elevated calprotectin and neutrophil extracellular traps (NETs)) could predict response to baricitinib
- CRP could not distinguish responders from nonresponders
- RA vs Healthy controls: P < 0.001
Original publication
Neutrophil Activation Markers and Rheumatoid Arthritis Treatment Response to the JAK1/2 Inhibitor Baricitinib. Arthritis Rheumatol. Published 17 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →